65,437 trials
Cataract
Primary: Near Best Corrected Visual Acuity (BCVA) - Binocular — 87.5; 100 Percentage of Participants
Grade I/II Ankle Sprain
Primary: Measure: Pain on Movement on Day 5 (Change From Baseline). — 49.1; 49.7; 25.4 mm
Renal Transplantation
Primary: Number of Participants Considered in Failure for the Primary Failure Endpoint at 3 Months — 36; 47; 16; 18 Participants
Urinary Bladder, Overactive
Primary: Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12 — -3.26 Number of Episodes
Hypertension
Primary: Change From Baseline in Trough Seated DBP at Week 8(LOCF). — -11.1; -7.3 mm Hg — p=<0.0001
Healthy
Primary: AUCt of Buprenorphine With and Without Ketoconazole. — 16354.8; 16627.9 pg/mL*h
Coronary Heart Disease
Primary: Cholesteryl Ester Fractional Clearance Rate
Scarring · Impaired Wound Healing
Primary: Time to Complete Wound Closure Collagenase Santyl and Vehicle — 12.9; 13.0 Days — p=<0.05
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 36; 23 participants
Warts · HPV
Primary: Number of Participants With Clinical Resolution of Injected Wart — 9; 1; 1 Participants
Candidiasis · Candidemia
Primary: Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration — 21.42 μg*h/mL
Toothache
Primary: Summed Pain Intensity Difference (SPID) — 25.9; -3.1; 8.8; -1.0 units on a scale — p=<0.001
Hemorrhage
Primary: The Amount of Hemorrhage During Cesarean Delivery and Within 2 Hours Afterward — 260; 380 ml
Polypoidal Choroidal Vasculopathy
Primary: Number of Participants With Complete Regression (CR) of Polyps Measured by Indocyanine Green Angiography (ICGA) — 14; 15; 6 Participants
Uremic Pruritus
Primary: Visual Analogue Scale (VAS) Score for Pruritus — -3.38; -3.53 Units on a scale — p=<0.05